- DBV Technologies (DBVT, Financial) has filed its 2024 Annual Report on Form 10-K and the Universal Registration Document (URD).
- The audited financial statements for the year ended December 31, 2024, were approved with no changes from the unaudited statements.
- Key reports include the Annual Financial Report, Management Report, Corporate Governance Report, and Share Buyback Program.
DBV Technologies (DBVT), a clinical-stage biopharmaceutical company, has officially filed its 2024 Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (SEC) and the Universal Registration Document (URD) with the French Autorité des Marchés Financiers (AMF). The Board of Directors approved the company's audited financial statements for the year ended December 31, 2024, on April 11, 2025, confirming no changes from the unaudited statements released on March 24, 2025.
The 2024 URD includes detailed insights such as the Annual Financial Report, Management Report, Corporate Governance Report, and a description of the Share Buyback Program. These documents are accessible through DBV Technologies’ website, while the URD can be found on the AMF’s website and the Form 10-K on the SEC’s portal. Additionally, investors and interested parties can obtain free printed copies at DBV's headquarters in Châtillon, France.
DBV Technologies focuses on developing treatments for food allergies and other immunologic conditions using its proprietary VIASKIN® patch technology. The company is actively exploring new treatment options through epicutaneous immunotherapy (EPIT™) to help individuals manage severe allergic reactions by re-educating the immune system.
